Five Prime Therapeutics, Inc.

RA Capital Management, LLC (“RA Capital”) is a crossover fund manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with minimal capital concerns from inception through commercialization.

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Magnetar Financial implements a variety of different strategies in managing private investment funds and separately managed accounts (SMAs) which designed to achieve attractive risk-adjusted rates of return. Some of the funds and SMAs employ a multi-strategy approach, utilizing a wide range of strategies across a range of geographies, while others focus on one or just a few strategies. It may hold both long and short positions in a broad range of securities, derivatives, and other assets. In executing their investment strategies, the funds and SMAs may enter into joint venture or co-investment arrangements, participate in pooled investment vehicles, invest with affiliated or unaffiliated advisors or managers, or make direct investments in operating entities. The firm’s main investment strategies are divided into the following categories: relative-value, event-driven, directional, hybrid and other investment strategies.

Founded in 1992, TPG specializes in recognizing value – or the potential for value – where others do not. Our contrarian philosophy, global reach, and deep investment and operational expertise set TPG apart from other firms. Our complementary asset classes offer a unique investment platform. TPG has an extensive global network and long-standing, on-the-ground presence in critical markets. TPG has built a strong international presence with 17 offices in 10 countries. We were one of the first U.S.-based private investment firms to establish significant operations in Asia and Europe, in 1994 and 1995 respectively.

Versant Ventures is an active manager which invests in healthcare companies located across the globe. The firm follows of companies operating in the fields of biotechnology sector such as biopharmaceutical, medical device, and healthcare services/HCIT companies. It provides financing for all stages of company development.

Healthcap is an active, long-term manager which invests in pharmaceutical, biotechnology and medical technology companies globally. As a multi-stage fund, the firm provides and participates in financing through all stages of company evolution. Their funds have no geographic restrictions.Healthcap's main investment style is to be lead investor and the firm acts predominantly as an influential minority investor, seeking to invest in the commercialization of innovations in medical science where they believe that the structural changes taking place in the pharmaceutical industry create significant opportunities for knowledgeable investors to achieve high financial returns.The firm partners with investee companies and founders, seeking board representation to assist with strategy formulation in the areas of science, business development and finance. They encourage substantial ownership by entrepreneurs and scientific founders and insist on implementing employee equity ownership programs to attract and reward key personnel.Healthcap's in-house science team evaluates the scientific merits of investment proposals and their in-house transaction team structures the transactions. The firm invests independently or in partnership with other investor groups.